Jubilant Ingrevia Limited has announced its entry into a Share Purchase Agreement with Remidex Pharma Private Limited ('Remidex') for the acquisition of its 100% stake. This strategic move will make Remidex a wholly-owned subsidiary of Jubilant Ingrevia. Remidex Pharma Private Limited, incorporated in 1981, is engaged in the manufacturing and selling of micronutrient premixes and nutraceuticals, and also operates as a contract manufacturing organization for pharmaceutical companies. In FY 2024-25, Remidex reported a turnover of ₹24.27 crore. The acquisition falls within the Human Nutrition - Premix and Pharmaceutical manufacturing industry. The primary objective of this acquisition is to enable Jubilant Ingrevia to advance its position in the value chain for premixes within the Human Nutrition sector, building on its existing leadership in Vitamins B3 and B4. The company has confirmed that this transaction does not involve related parties or promoters' interests and is conducted at an arm's length. The acquisition involves a cash consideration of ₹16.5 crore, subject to customary closing conditions. Jubilant Ingrevia will acquire 100% of the equity shares of Remidex. The company anticipates completing the acquisition within 30 days from the announcement. Remidex possesses a manufacturing facility in Bangalore with certifications such as WHO-GMP, FSSC, and FSSAI, and serves a marquee customer base. For the last three financial years, Remidex's turnover was ₹24.27 crore (FY24-25), ₹31.15 crore (FY23-24), and ₹30.51 crore (FY22-23).
